Galderma Reports Positive Results for Facial Volume Loss Tied to Medication-Driven Weight Loss
The phase IV trial evaluated outcomes of Sculptra plus Restylane Lyft or Contour in patients with facial volume loss due to weight loss medications.
The phase IV trial evaluated outcomes of Sculptra plus Restylane Lyft or Contour in patients with facial volume loss due to weight loss medications.
The botulinum neurotoxin type E candidate is designed for a faster onset and shorter duration of effect than currently available neurotoxin treatments.